Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2009

Odyssey Thera to Help Mitsubishi Tanabe Pharma with Preclinical Research

  • Odyssey Thera will analyze drug candidates from a number of preclinical programs for Mitsubishi Tanabe Pharma. Odyssey Thera will apply its patented protein-fragment complementation assay, high-context screening infrastructure, institutional knowledge, and data analysis strategies in the collaboration to yield insights related to drug selectivity, safety, and mechanisms of action.

    Odyssey also reports the issuance of a Japanese patent entitled, “Protein fragment complementation assays for the detection of biological or drug interactions.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »